PL3851537T3 - Leczenie hiperbilirubinemii - Google Patents

Leczenie hiperbilirubinemii

Info

Publication number
PL3851537T3
PL3851537T3 PL21151019.3T PL21151019T PL3851537T3 PL 3851537 T3 PL3851537 T3 PL 3851537T3 PL 21151019 T PL21151019 T PL 21151019T PL 3851537 T3 PL3851537 T3 PL 3851537T3
Authority
PL
Poland
Prior art keywords
hyperbilirubinemia
treatment
Prior art date
Application number
PL21151019.3T
Other languages
English (en)
Inventor
Federico Mingozzi
Giuseppe RONZITTI
Fanny COLLAUD
Andrés MURO
Giulia BORTOLUSSI
Original Assignee
Genethon
International Centre For Genetic Engineering And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon, International Centre For Genetic Engineering And Biotechnology filed Critical Genethon
Publication of PL3851537T3 publication Critical patent/PL3851537T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • C12Y204/01017Glucuronosyltransferase (2.4.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21151019.3T 2014-04-25 2015-04-27 Leczenie hiperbilirubinemii PL3851537T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305622 2014-04-25
EP14196400 2014-12-04

Publications (1)

Publication Number Publication Date
PL3851537T3 true PL3851537T3 (pl) 2024-09-16

Family

ID=53039406

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21151019.3T PL3851537T3 (pl) 2014-04-25 2015-04-27 Leczenie hiperbilirubinemii

Country Status (11)

Country Link
US (3) US10471132B2 (pl)
EP (3) EP3134530B1 (pl)
JP (3) JP6730193B2 (pl)
CN (2) CN106459932B (pl)
AU (1) AU2015250770B2 (pl)
CA (2) CA3205555A1 (pl)
DK (2) DK3851537T5 (pl)
ES (2) ES2744565T3 (pl)
FI (1) FI3851537T3 (pl)
PL (1) PL3851537T3 (pl)
WO (1) WO2015162302A2 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hiv予備免疫化および免疫療法
EP3386533A1 (en) * 2015-12-09 2018-10-17 ModernaTX, Inc. Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof
US11241506B2 (en) * 2015-12-14 2022-02-08 The Trustees Of The University Of Pennsylvania Composition for treatment of Crigler-Najjar syndrome
WO2017108931A1 (en) * 2015-12-22 2017-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
CN108883100B (zh) 2016-01-15 2022-11-25 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
CN105721252B (zh) * 2016-03-24 2020-09-25 腾讯科技(深圳)有限公司 数据包乱序度的测量方法和系统
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
PE20191203A1 (es) 2016-09-12 2019-09-10 Genethon Variantes de alfa-glucosidasa acida y usos de las mismas
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
CA3053455A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
EP4450078A2 (en) * 2017-07-07 2024-10-23 Genethon Novel polynucleotides encoding a human fkrp protein
US20200318081A1 (en) * 2017-10-02 2020-10-08 American Gene Technologies International Inc. Vectors with promoter and enhancer combinations for treating phenylketonuria
EP3749771A1 (en) 2018-02-07 2020-12-16 Genethon Hybrid regulatory elements
JP7142815B2 (ja) * 2018-06-21 2022-09-28 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
CN109082402B (zh) * 2018-08-06 2021-08-17 复旦大学 一种aav-dj型腺相关病毒体外高效感染类器官的用途
CA3107572A1 (en) 2018-08-08 2020-02-13 Genethon Mini-gde for the treatment of glycogen storage disease iii
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CA3113817A1 (en) * 2018-10-09 2020-04-16 The University Of North Carolina At Chapel Hill Regulated gene editing system
EP3898995A1 (en) * 2018-12-21 2021-10-27 Genethon Expression cassettes for gene therapy vectors
IT201900008877A1 (it) * 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
EP4048786A1 (en) 2019-10-22 2022-08-31 Genethon Chimeric polypeptides and uses thereof
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
EP4200410A1 (en) 2020-08-24 2023-06-28 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
WO2022076556A2 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2022177597A1 (en) * 2021-02-16 2022-08-25 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to enhance rna stability and translation and uses thereof
WO2023237731A1 (en) 2022-06-09 2023-12-14 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6067590A (en) * 1989-07-24 1991-02-22 Seragen, Inc. Prevention of internal initiation
JP2000501614A (ja) * 1995-12-15 2000-02-15 システミックス,インコーポレイテッド 高形質導入効率を有するレトロウイルスベクター上清を得るための方法
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
CA2425852C (en) * 2000-10-13 2009-09-29 Chiron Corporation Cytomegalovirus intron a fragments
ES2647477T3 (es) 2004-06-01 2017-12-21 Genzyme Corporation Composiciones y métodos para prevenir la agregación del vector AAV
US20100028312A1 (en) * 2005-03-24 2010-02-04 Caritas St. Elizabeth Medical Center of Boston Inc Stably transformed bone marrow-derived cells and uses thereof
US20100196335A1 (en) * 2005-04-29 2010-08-05 Samulski Richard J Methods and Compositions for Regulated Expressions of Nucleic Acid at Post-Transcriptional Level
US8129510B2 (en) * 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
KR101229418B1 (ko) * 2007-06-15 2013-02-05 재단법인 목암생명공학연구소 활성형 재조합 혈액응고 9인자의 대량생산 방법
EP2014301A1 (en) * 2007-07-13 2009-01-14 TopoTarget Germany AG Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
CN101348786B (zh) * 2007-07-20 2011-05-11 谭孟群 一种人β珠蛋白基因及其重组腺相关病毒载体
KR20110086553A (ko) * 2008-09-29 2011-07-28 암스테르담 몰레큘러 테라퓨틱스 비. 브이. 포르포빌리노겐 디아미나아제 유전자 치료
CN101671740B (zh) * 2009-10-19 2012-05-23 广州益善生物技术有限公司 Ugt1a1基因多态性检测的方法及液相芯片
WO2011057119A1 (en) * 2009-11-06 2011-05-12 Enzymatics, Inc. Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase
WO2011106759A1 (en) 2010-02-26 2011-09-01 The Children's Hospital Of Philadelphia Protein c zymogen and methods of use thereof to prevent cancer metastases
US9265813B2 (en) * 2011-10-27 2016-02-23 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
CN102643906A (zh) * 2012-04-01 2012-08-22 周宏灏 焦磷酸测序法检测伊立替康个体化用药基因多态性的试剂盒及方法
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2014017493A1 (ja) * 2012-07-23 2014-01-30 有限会社生物資源研究所 ワクチン
CN103146804B (zh) * 2013-02-04 2015-04-22 中国科学院大连化学物理研究所 葡萄糖醛酸转移酶ugt1a1的特异性探针底物及应用
MX2016001044A (es) 2013-07-22 2016-09-09 The Children's Hospital Of Philadelphia Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos.
CN104789532B (zh) * 2015-03-30 2019-06-11 汉恒生物科技(上海)有限公司 一种表达腺病毒的细胞株及高效制备腺病毒的方法

Also Published As

Publication number Publication date
CA3205555A1 (en) 2015-10-29
WO2015162302A2 (en) 2015-10-29
US10471132B2 (en) 2019-11-12
CN106459932B (zh) 2022-01-11
JP7349931B2 (ja) 2023-09-25
EP3851537B1 (en) 2023-12-27
DK3851537T3 (da) 2024-03-18
US20190374619A1 (en) 2019-12-12
CA2942451A1 (en) 2015-10-29
EP3134530A2 (en) 2017-03-01
EP3134530B1 (en) 2019-06-12
US20170028036A1 (en) 2017-02-02
JP6730193B2 (ja) 2020-07-29
DK3851537T5 (da) 2024-08-19
US20230414724A1 (en) 2023-12-28
JP2020103300A (ja) 2020-07-09
EP3851537A1 (en) 2021-07-21
EP3546585A1 (en) 2019-10-02
CN106459932A (zh) 2017-02-22
JP2022088645A (ja) 2022-06-14
FI3851537T3 (fi) 2024-03-21
DK3134530T3 (da) 2019-09-09
ES2744565T3 (es) 2020-02-25
CN114395559A (zh) 2022-04-26
AU2015250770B2 (en) 2020-10-01
JP2017513501A (ja) 2017-06-01
AU2015250770A1 (en) 2016-09-29
WO2015162302A3 (en) 2015-12-30
ES2971434T3 (es) 2024-06-05

Similar Documents

Publication Publication Date Title
PL3851537T3 (pl) Leczenie hiperbilirubinemii
IL252839A0 (en) Treatment of boils
GB201701673D0 (en) Methods of well treatment
IL250677B (en) Cancer treatment using anti-nkg2a agents
PT3212233T (pt) Terapia combinada para o tratamento de doenças
SI3122358T1 (sl) Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
IL248856B (en) New treatment
HK1244711A1 (zh) Hmgb1介導的炎症的治療
GB201416832D0 (en) Methods of treatment
IL246880A0 (en) Tumor treatment
GB201408297D0 (en) Treatment of cancer
GB201410407D0 (en) Treatment of chagas disease
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201417456D0 (en) Treatment of cancer
GB201512139D0 (en) Methods of treatment
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201417465D0 (en) Treatment of cancers
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201412285D0 (en) Therapeutic treatments
GB201412293D0 (en) Therapeutic treatments